（来源：经济参考报） 前不久，招商信诺人寿保险有限公司（以下简称"招商信诺"）与新华社旗下经济参考报/新华健康平台 （以下简称"新华健康"）联合发布了《2025中国企业健康保障发展白皮书》（以下简称"白皮书"），从 政策、市场、企业实践等多角度展开深入探讨。作为白皮书指导专家之一，朱铭来评价说，这份报告不 仅分析了企业健康保障的最新趋势与实践，提供了翔实的数据与案例，同时也创新性地提出了以团体保 险为核心的产品与服务体系解决方案。 "在政策支持与需求升级的双重驱动下，企业健康保障体系正向多元化、精细化演进，但仍需政府、企 业、保险机构等多方协同，以推动多层次医疗保障体系持续完善。"他说。 南开大学卫生经济与医疗保障研究中心主任朱铭来教授近日表示，中国商业健康保险正处于规模增长的 关键拐点，团体补充医疗保险改革是解决当前困境的重要突破口，"建议明确团体补充医疗保险的制度 定位，优化财税激励政策，并建立标准化产品体系；保险行业开发分层分类的团体补充医疗保险产品； 搭建公共数据和健康保险交易平台，提高市场服务效率、降低保险经营成本"。 当前，以基本医疗保险为主体、多种保障形式协同发展的制度框架，为企业构建补充健康保 ...

（来源：经济参考报） 随着我国步入高质量发展阶段，企业健康保障已从一项"行政成本"，转变为关乎人才竞争与组织发展 的"战略投资"，并迎来历史性发展机遇。 日前，招商信诺人寿保险有限公司（以下简称"招商信诺"）携手新华社旗下经济参考报/新华健康平台 （以下简称"新华健康"）发布的《2025中国企业健康保障发展白皮书》（以下简称"白皮书"）揭示了这 一关键转变， 并认为行业已进入"垂直化、精准化"深耕期，"千企千面"的差异化解决方案至关重要。 南开大学卫生经济与医疗保障研究中心主任朱铭来教授则表示，中国商业健康保险正处于规模增长的关 键拐点，团体补充医疗保险改革是解决当前困境的重要突破口。"建议明确团体补充医疗保险的制度定 位，优化财税激励政策，并建立标准化产品体系；保险行业开发分层分类的团体补充医疗保险产品；搭 建公共数据和健康保险交易平台，提高市场服务效率、降低保险经营成本"。 核心发现：从"行政成本"到"战略资产" 据悉，白皮书由国家卫健委卫生发展研究中心、复旦大学、南开大学的权威专家共同指导编写，主要聚 焦企业健康保障体系的建设现状与发展趋势。 调研样本：从全球员工到本土企业 作为专业的大健康解决方案供应 ...

Group 1 - The article discusses the significant opportunities and challenges faced by commercial health insurance in China due to the multi-dimensional drivers of healthcare reform and high-quality development in the medical and pharmaceutical industries [1] - It identifies the "adverse selection" problem in the personal commercial health insurance market as the root cause of high operational costs, low service efficiency, weak cost control, and limited coverage [1] - The article compares the development experiences of seven typical countries or regions, highlighting that a prosperous commercial health insurance market relies on various forms of government support [1] Group 2 - It emphasizes that a reasonable tax incentive policy and a shared payment model between employers and employees are crucial for the sustainable development of commercial health insurance [1] - The article proposes establishing a shared, account-based funding model to leverage corporate or institutional funding, thereby expanding the coverage and funding scale of commercial supplementary health insurance [1] - It suggests reforming the second pillar of enterprise group supplementary health insurance to provide new theoretical guidance and practical paradigms for the high-quality collaborative development of healthcare, pharmaceuticals, and insurance [1] Group 3 - The article analyzes Australia's high coverage policy for commercial health insurance, which includes various incentives and penalties to maintain coverage rates [3] - It notes that these policies have prevented the Australian commercial health insurance market from falling into a "death spiral," offering valuable insights for the sustainable development of China's health insurance initiatives [3] Group 4 - The article on Mexico's dual healthcare system highlights the disparities in funding and benefits between formal and informal employment populations, leading to sustainability issues [5] - It discusses the failure of the new INSABI system due to funding shortages and centralized management, resulting in a significant drop in coverage rates [5] - The article suggests measures to optimize and integrate the healthcare system, such as including family members of formal employees in the formal healthcare system and implementing regionally differentiated payment mechanisms [5] Group 5 - The article on poultry insurance emphasizes the importance of developing the poultry industry and adjusting breeding structures in China [6] - It identifies a mismatch between the current poultry insurance offerings and the actual risk management needs of poultry farmers [6] - Recommendations include enhancing government support, improving the poultry insurance service system, and aligning insurance products with industry development needs [6] Group 6 - The article on weather index insurance in Zhuhai discusses its role in supporting local aquaculture and stabilizing farmer incomes [7] - It identifies various risks faced by underwriting institutions, including natural disaster unpredictability and basis risk due to mismatches between weather indices and actual losses [7] - The article recommends strengthening meteorological monitoring systems and optimizing insurance product designs to mitigate these risks [7] Group 7 - The article on patent insurance highlights its significance in protecting intellectual property and supporting technological innovation [8] - It identifies challenges such as insufficient recognition of demand and a lack of market mechanisms that hinder the development of patent insurance [8] - Recommendations include building a comprehensive patent risk management platform and enhancing public awareness of patent insurance [8] Group 8 - The article on motor vehicle insurance fraud analyzes the increasing prevalence of fraud in the insurance industry, which disrupts market order and harms economic interests [10] - It identifies systemic issues such as ineffective underwriting processes and lack of supervision in claims handling [10] - The article proposes a multi-faceted approach to combat fraud, including legal reforms, technology integration, and public education [10] Group 9 - The article on exemption clauses in insurance contracts discusses their role in defining the insurer's liability and the disputes that arise from their complexity [11] - It emphasizes the need for clear understanding and application of these clauses to reduce market instability [11] - The article suggests establishing uniform standards for interpreting exemption clauses, especially in the context of internet insurance [11] Group 10 - The article on illegal "agent refund" practices highlights the systemic gaps in the insurance sales process that allow such issues to persist [12] - It calls for a comprehensive regulatory framework to protect consumer interests and enhance the integrity of the insurance market [12] - Recommendations include balancing consumer data protection with its utilization and expanding the obligations of insurance companies during sales [12]

Group 1 - The core viewpoint of the article emphasizes the high-quality collaborative development between commercial health insurance and the pharmaceutical industry, highlighting the interdependent relationship between medical service providers and insurance payment entities [1] - The historical development of the medical service system and the pharmaceutical industry reveals a complex interplay with insurance payment mechanisms, indicating potential areas for collaboration and growth [1][2] - The transition from a government-subsidized healthcare model to a market-driven approach has led to significant changes in the operational dynamics of public hospitals and the pharmaceutical sector [3][4] Group 2 - The period from 2009 to 2017 marked a significant phase in the reform of public hospital compensation mechanisms, with a focus on balancing the roles of medical service providers and insurance payers [9][10] - The introduction of the "New Medical Reform" in 2009 aimed to establish a public health service system that covers urban and rural residents, although challenges in implementation persisted [9][14] - The commercial health insurance market experienced substantial growth during this period, with premiums increasing tenfold, reflecting a rising demand for supplementary health coverage [6][15] Group 3 - The establishment of the National Healthcare Security Administration in 2018 initiated a new phase of medical reform, introducing diverse payment methods and enhancing regulatory oversight of healthcare expenditures [20][21] - The shift towards a more refined management approach in healthcare institutions is driven by the need to control costs and improve service quality, influenced by changes in insurance payment structures [23][24] - The integration of commercial health insurance with the healthcare system is expected to accelerate, particularly in the high-end medical service sector, as consumer demand for quality healthcare rises [26][27] Group 4 - The pharmaceutical industry in China has undergone significant transformations, with a notable shift towards biopharmaceuticals and innovative drug development, supported by government policies [30][31] - The rapid growth of the Chinese pharmaceutical market has positioned it as the second-largest globally, with a compound annual growth rate of 7.8% from 2010 to 2020 [31][33] - Despite the overall market expansion, challenges such as structural oversupply and the need for higher-quality products remain prevalent, necessitating ongoing industry adjustments [33][34]